Nov-30-18 Antibe Therapeutics to Present at the 11th Annual LD Micro Main Event on December 4, 2018
Nov-27-18 Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Nov-23-18 Antibe Therapeutics Reports Q2 2019 Interim Financial and Operating Results
Oct-22-18 Antibe Therapeutics Establishes Business Development Advisory Board
Oct-10-18 Antibe Therapeutics Receives Approval to Initiate Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Oct-03-18 Antibe Therapeutics Announces Grant of Restricted Share Units
Sep-05-18 Antibe Therapeutics Announces Strategic Licensing Deal for Lead Drug in South Korea
Aug-29-18 Antibe Therapeutics Reports Q1 2019 Interim Financial and Operating Results
Aug-29-18 Antibe Provides Scientific Report on its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346
Jul-31-18 Antibe Therapeutics Provides Clinical Development Update on its Lead Drug
Jul-06-18 Antibe Completes Share Issuance in Connection with Citagenix Credit Facility
Jul-03-18 Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346
Jun-29-18 Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results
Jun-26-18 Antibe Therapeutics Announces Results of Annual General and Special Meeting
Jun-04-18 Antibe Therapeutics to Attend 2018 BIO International Convention to Support Partnering Efforts
May-29-18 Antibe’s Chief Scientific Officer to Present at 5th World Congress on Hydrogen Sulfide in Biology and Medicine
May-24-18 Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology
Apr-30-18 Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference
Apr-26-18 Antibe Therapeutics Announces CEO Letter to Shareholders
Apr-11-18 Antibe Therapeutics Engages Blaise Group International for Executive Search